49 results on '"James, Ian E."'
Search Results
2. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers
3. The application of immunocytochemistry and in situ hybridization to cryostat sections of undecalcified bone
4. Novel inhibitors of the osteoclast specific cysteine protease, cathepsin K
5. Two‐Part Phase 1 Multiple‐Ascending‐Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults
6. Mechanical Injury Potentiates Proteoglycan Catabolism Induced by Interleukin-6 With Soluble Interleukin-6 Receptor and Tumor Necrosis Factor α in Immature Bovine and Adult Human Articular Cartilage
7. Two‐Part Phase 1 Multiple‐Ascending‐Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults.
8. Design of potent and selective human cathepsin K inhibitors that span the active site
9. Proteoglycan Degradation After Injurious Compression of Bovine and Human Articular Cartilage In Vitro: Interaction With Exogenous Cytokines
10. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats
11. A First‐in‐Human Clinical Study With TRV734, an Orally Bioavailable G‐Protein–Biased Ligand at the μ‐Opioid Receptor
12. Novel bone antiresorptive approaches
13. Potent and Selective Cathepsin L Inhibitors Do Not Inhibit Human Osteoclast Resorption in Vitro
14. Injurious Mechanical Compression of Bovine Articular Cartilage Induces Chondrocyte Apoptosis
15. A First‐in‐Human Clinical Study With TRV734, an Orally Bioavailable G‐Protein–Biased Ligand at the μ‐Opioid Receptor.
16. Identification and Cloning of a Connective Tissue Growth Factor-like cDNA from Human Osteoblasts Encoding a Novel Regulator of Osteoblast Functions
17. Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
18. Novel inhibitors of the osteoclast specific cysteine protease, cathepsin K
19. The application of immunocytochemistry and in situ hybridization to cryostat sections of undecalcified bone
20. TRVO27, A BETA-ARRESTIN BIASED LIGAND AT THE ANGIOTENSIN 2 TYPE 1 RECEPTOR, PRODUCES RAPID, REVERSIBLE CHANGES IN HEMODYNAMICS IN PATIENTS WITH STABLE SYSTOLIC HEART FAILURE
21. A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes
22. Osteopontin deposition in remodeling bone: An osteoclast mediated event
23. Purification and characterization of fully functional human osteoclast precursors
24. Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone
25. Structure Activity Relationships of 5-, 6-, and 7-Methyl-Substituted Azepan-3-one Cathepsin K Inhibitors
26. An Azepanone-Based Inhibitor of Human Cathepsin K with Improved Oral Bioavailability in the Rat and the Monkey
27. Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.
28. Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists
29. Potent and Selective Inhibition of Human Cathepsin K Leads to Inhibition of Bone Resorption In Vivo in a Nonhuman Primate
30. Human Osteoclast Cathepsin K Is Processed Intracellularly Prior to Attachment and Bone Resorption
31. Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat
32. CKβ-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues
33. Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic
34. Development and Characterization of a Human In Vitro Resorption Assay: Demonstration of Utility Using Novel Antiresorptive Agents
35. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
36. Peptide Aldehyde Inhibitors of Cathepsin K Inhibit Bone Resorption Both In Vitro and In Vivo
37. Cloning and Characterization of a Novel Integrin β3Subunit
38. Human osteoclastoma-derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo
39. Cathepsin K, but Not Cathepsins B, L, or S, Is Abundantly Expressed in Human Osteoclasts
40. Monoclonal antibodies with selective reactivity against osteoblasts and osteocytes in human bone
41. The application of immunocytochemistry and in situ hybridization to cryostat sections of undecalcified bone.
42. Mechanical Injury Potentiates Proteoglycan Catabolism Induced by Interleukin-6 With Soluble Interleukin-6 Receptor and Tumor Necrosis Factor a in Immature Bovine and Adult Human Articular Cartilage.
43. Purification and characterization of fully functional human osteoclast precursors.
44. Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone.
45. Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling bone
46. Osteopontin deposition in remodeling bone: An osteoclast mediated event.
47. Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage.
48. An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.
49. Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.